NCT03850418

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (estimated)
• Sponsor: Henry Ford Health System · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD

Conditions

• Myeloid Malignancy

Interventions

Type	Name	Description
DRUG	azacitidine	azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated

Timeline

• Start date: 2019-07-01
• Primary completion: 2028-02-20
• Completion: 2028-02-20
• First posted: 2019-02-21
• Last updated: 2026-02-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study